Cancanelli, L.; Rivano, M.; Di Spazio, L.; Chiumente, M.; Mengato, D.; Messori, A. Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematol. Rep.2023, 15, 57-65.
Cancanelli, L.; Rivano, M.; Di Spazio, L.; Chiumente, M.; Mengato, D.; Messori, A. Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematol. Rep. 2023, 15, 57-65.
Cancanelli, L.; Rivano, M.; Di Spazio, L.; Chiumente, M.; Mengato, D.; Messori, A. Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematol. Rep.2023, 15, 57-65.
Cancanelli, L.; Rivano, M.; Di Spazio, L.; Chiumente, M.; Mengato, D.; Messori, A. Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematol. Rep. 2023, 15, 57-65.
Abstract
In recent years, new treatments have been studied for relapsed-refractory multiple myeloma (RRMM), including two CAR-T products and a variety of non CAR-T agents. Since direct comparisons between these innovative treatments are not available, indirect comparisons can be of interest. Reconstruction of individual patient data from Kaplan-Meier graphs (Shiny method) has been employed in numerous reports that have validated its performance. In the present review, we evaluated six treatments proposed for RRMM including two CAR-T products (ciltacabtagene autoleucel and idecabtagene vicleucel) and four treatments not based on a CAR-T (melflufen plus dexamethasone, isatuximab plus dexamethasone, selinexor, and belantamab). The end-point was overall survival (OS); the Shiny method was used to generate reconstructed survival curves. Our results showed statistically significant differences in OS across these treatments. Compared with pharmacological treatments, CAR-T products significantly prolonged OS with an improvement of remarkable clinical relevance. In particular, ciltacabtagene autoleucel showed better OS than idecabtagene vicleucel. As regards non CAR-T treatments, the ranking in OS was headed by isatuximab plus dexamethasone, followed by belantamab, selinexor, and melflufen plus dexamethasone. In conclusion, while the Shiny method has confirmed its validity in reconstructing individual patient data, our indirect comparisons have offered some original clues to better interpret the information on OS published in these studies.
Keywords
relapsed-refractory multiple myeloma; overall survival; CAR-T; non CAR-T agents
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
